|
1.Ullrich, A. and J. Schlessinger, Signal transduction by receptors with tyrosine kinase activity. Cell, 1990. 61(2): p. 203-12.
2.Olayioye, M.A., et al., The ErbB signaling network: receptor heterodimerization in development and cancer. The EMBO Journal, 2000. 19(13): p. 3159-67.
3.O-charoenrat, P., et al., The role of c-erbB receptors and ligands in head and neck squamous cell carcinoma. Oral Oncology, 2002. 38(7): p. 627-40.
4.Guy, P.M., et al., Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proceedings of the National Academy of Sciences of the United States of America, 1994. 91(17): p. 8132-6.
5.Alimandi, M., et al., Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene, 1995. 10(9): p. 1813-21.
6.deFazio, A., et al., Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines. International journal of cancer. Journal international du cancer, 2000. 87(4): p. 487-98.
7.Naidu, R., et al., Expression of c-erbB3 protein in primary breast carcinomas. British Journal of Cancer, 1998. 78(10): p. 1385-90.
8.Woodhouse, E.C., R.F. Chuaqui, and L.A. Liotta, General mechanisms of metastasis. Cancer, 1997. 80(8 Suppl): p. 1529-37.
9.Chambers, A.F., A.C. Groom, and I.C. MacDonald, Dissemination and growth of cancer cells in metastatic sites. Nature Reviews. Cancer, 2002. 2(8): p. 563-72.
10.Hanahan, D. and R.A. Weinberg, The hallmarks of cancer. Cell, 2000. 100(1): p. 57-70.
11.Pantel, K. and R.H. Brakenhoff, Dissecting the metastatic cascade. Nature Reviews. Cancer, 2004. 4(6): p. 448-56.
12.Chambers, A.F. and L.M. Matrisian, Changing views of the role of matrix metalloproteinases in metastasis. Journal of the National Cancer Institute, 1997. 89(17): p. 1260-70.
13.Duffy, M.J. and K. McCarthy, Matrix metalloproteinases in cancer: prognostic markers and targets for therapy (review). International Journal of Oncology, 1998. 12(6): p. 1343-8.
14.Egeblad, M. and Z. Werb, New functions for the matrix metalloproteinases in cancer progression. Nature Reviews. Cancer, 2002. 2(3): p. 161-74.
15.Sternlicht, M.D. and Z. Werb, How matrix metalloproteinases regulate cell behavior. Annual Review of Cell and Developmental Biology, 2001. 17: p. 463-516.
16.Lee, P.P., et al., Functional significance of MMP-9 in tumor necrosis factor-induced proliferation and branching morphogenesis of mammary epithelial cells. Endocrinology, 2000. 141(10): p. 3764-73.
17.Waas, E.T., et al., Tissue levels of active matrix metalloproteinase-2 and -9 in colorectal cancer. British Journal of Cancer, 2002. 86(12): p. 1876-83.
18.Brew, K., D. Dinakarpandian, and H. Nagase, Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochimica Et Biophysica Acta, 2000. 1477(1-2): p. 267-83.
19.Nagase, H. and J.F. Woessner, Matrix metalloproteinases. The Journal of Biological Chemistry, 1999. 274(31): p. 21491-4.
20.Basset, P., et al., Matrix metalloproteinases as stromal effectors of human carcinoma progression: therapeutic implications. Matrix Biology: Journal of the International Society for Matrix Biology, 1997. 15(8-9): p. 535-41.
21.Johnsen, M., et al., Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation. Current Opinion in Cell Biology, 1998. 10(5): p. 667-71.
22.Rimando, A.M., et al., Cancer chemopreventive and antioxidant activities of pterostilbene, a naturally occurring analogue of resveratrol. Journal of Agricultural and Food Chemistry, 2002. 50(12): p. 3453-7.
23.Jang, M. and J.M. Pezzuto, Cancer chemopreventive activity of resveratrol. Drugs Under Experimental and Clinical Research, 1999. 25(2-3): p. 65-77.
24.Pace-Asciak, C.R., et al., Wines and grape juices as modulators of platelet aggregation in healthy human subjects. Clinica Chimica Acta; International Journal of Clinical Chemistry, 1996. 246(1-2): p. 163-82.
25.Soleas, G.J., E.P. Diamandis, and D.M. Goldberg, Wine as a biological fluid: history, production, and role in disease prevention. Journal of Clinical Laboratory Analysis, 1997. 11(5): p. 287-313.
26.Suh, N., et al., Pterostilbene, an active constituent of blueberries, suppresses aberrant crypt foci formation in the azoxymethane-induced colon carcinogenesis model in rats. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 2007. 13(1): p. 350-5.
27.Tsai, M.-S., et al., Blockage of heregulin expression inhibits tumorigenicity and metastasis of breast cancer. Oncogene, 2003. 22(5): p. 761-8.
28.Price, J.E., Clonogenicity and experimental metastatic potential of spontaneous mouse mammary neoplasms. Journal of the National Cancer Institute, 1986. 77(2): p. 529-35.
29.Yao, J., et al., Multiple signaling pathways involved in activation of matrix metalloproteinase-9 (MMP-9) by heregulin-beta1 in human breast cancer cells. Oncogene, 2001. 20(56): p. 8066-74.
30.Scorilas, A., et al., Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients. British Journal of Cancer, 2001. 84(11): p. 1488-96.
31.Tang, F.-Y., E.-P.I. Chiang, and Y.-C. Sun, Resveratrol inhibits heregulin-beta1-mediated matrix metalloproteinase-9 expression and cell invasion in human breast cancer cells. The Journal of Nutritional Biochemistry, 2008. 19(5): p. 287-94.
32.Yu, H., et al., Resveratrol inhibits tumor necrosis factor-alpha-mediated matrix metalloproteinase-9 expression and invasion of human hepatocellular carcinoma cells. Biomedicine & Pharmacotherapy, 2008. 62(6): p. 366-72.
33.Lupu, R., et al., The significance of heregulin in breast cancer tumor progression and drug resistance. Breast Cancer Research and Treatment, 1996. 38(1): p. 57-66.
34.Tsai, M.-S., et al., Blockage of heregulin expression inhibits tumorigenicity and metastasis of breast cancer. Oncogene, 2003. 22(5): p. 761-8.
35.Price, J.E., Clonogenicity and experimental metastatic potential of spontaneous mouse mammary neoplasms. Journal of the National Cancer Institute, 1986. 77(2): p. 529-35.
|